Junaliza (Atorvastatin, Ezetimibe)

Junaliza combines atorvastatin and ezetimibe to lower lipid levels in disorders of cholesterol metabolism.

• Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol in patients with elevated cholesterol.
• Mixed dyslipidemia: improves both LDL‑cholesterol and triglyceride levels in individuals with combined lipid abnormalities.
• Familial hypercholesterolemia: provides additional LDL‑cholesterol reduction when diet and statin monotherapy are insufficient.

• Atorvastatin competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol synthesis, leading to up‑regulation of LDL receptors and increased clearance of circulating LDL particles. Ezetimibe selectively blocks the NPC1L1 transporter on enterocytes, reducing intestinal absorption of dietary and biliary cholesterol. The combined effect results in a greater reduction of plasma LDL‑cholesterol than either agent alone.

Junaliza may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate headache reported.
• Myalgia: muscle aches without significant CK elevation.
• Diarrhea: loose stools or increased bowel movements.
• Nausea: occasional feeling of sickness.
• Elevated liver enzymes: mild transaminase increases.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with high CK.
• Hepatotoxicity: marked elevation of liver enzymes or hepatitis.
• Acute renal failure: sudden loss of kidney function.
• Anaphylactic reaction: rare severe allergic response.
• Interstitial lung disease: uncommon pulmonary inflammation.

Before prescribing Junaliza, clinicians should consider several precautionary measures to ensure safe use.

• Liver function monitoring: assess baseline transaminases and repeat periodically.
• Renal impairment: adjust therapy in patients with severe kidney disease.
• Drug interactions: review concomitant medications that affect statin metabolism.
• Pregnancy and lactation: avoid use due to unknown safety profile.
• Muscle toxicity: discontinue if signs of myopathy or rhabdomyolysis appear.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Junaliza can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase atorvastatin exposure and risk of muscle toxicity.
• Gemfibrozil: markedly raises statin levels, heightening rhabdomyolysis risk.
• Cyclosporine: enhances both components, leading to hepatotoxicity and myopathy.

Moderate Interactions (Monitor Closely)

• Antacids (e.g., aluminum hydroxide): may reduce ezetimibe absorption.
• Warfarin: potential alteration of INR, requiring closer monitoring.
• Niacin: additive lipid‑lowering effect may increase muscle side effects.